The Trump administration, perhaps surprisingly, chose to defend the legality of the Inflation Reduction Act’s (IRA’s) drug price negotiation program enacted under President Joe Biden. | The Trump administration is adopting a similar legal framework as the Biden administration regarding the drug price negotiation program,

The U.S. Department of Justice has filed an appeals court brief supporting the right of Medicare officials to negotiate prescription drug prices, a sign that some consumer advocates said suggests the Trump administration is willing to maintain the controversial program.

Trump could either weaken the negotiations in a way that benefits the pharmaceutical industry, or try to achieve even deeper savings to outdo his predecessor.

The celebrity doctor said he would divest from his interests in many drug, medical and insurance companies, worth millions of dollars.

Responding to a lawsuit by Novartis (NVS), the U.S. Department of Justice has defended Medicare price negotiations, signaling that the controversial program introduced by former President Biden will continue under President Trump’s new administration.